155184-79-5

Basic information

• Product Name: Acetamide, N-(3-chloro-4-methylphenyl)-2-(hydroxyimino)-
• CAS NO: 155184-79-5
• Molecular Formula: C9H9ClN2O2
• Molecular Weight: 212.636
• Mol File: 155184-79-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Acetamide, N-(3-chloro-4-methylphenyl)-2-(hydroxyimino)-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-(3-chloro-4-methylphenyl)-2-(hydroxyimino)-(155184-79-5)
• EPA Substance Registry System: Acetamide, N-(3-chloro-4-methylphenyl)-2-(hydroxyimino)-(155184-79-5)

Safety Data

• Hazardous Substances Data: 155184-79-5(Hazardous Substances Data)

Upstream product

• 302-17-0 chloral hydrate 
• 7745-89-3 3-chloro-4-methylaniline hydrochloride 
• 75-87-6 chloral 
• 95-74-9 3-chloro-p-toluidine 

Downstream Products

• 53003-18-2 4-chloro-5-methyl-1H-indole-2,3-dione 
• 96187-75-6 6-chloro-5-methylisatin 
• 450407-83-7 2-(N-tert-butyloxycarbonyl)amino-5-methyl-6-chlorobenzoic acid 
• 450407-84-8 methyl 2-(N-tert-butyloxycarbonyl)amino-5-methyl-6-chlorobenzoate 
• 342411-56-7 methyl 2-amino-5-methyl-6-chlorobenzoate 
• 155184-81-9 2-amino-5-methyl-4-chlorobenzoic acid 
• 155184-82-0 2-amino-5-methyl-6-chlorobenzoic acid 

Relevant articles and documents

Synthesis and in vitro antitumor activity of thiophene analogues of 5-chloro-5,8-dideazafolic acid and 2-methyl-2-desamino-5-chloro-5,8-dideazafolic acid

N-[5-[N-(2-Amino-5-chloro-3,4-dihydro-4-oxoquinazolin-6-yl)methylamino]-2- thenoyl]-L-glutamic acid (6) and N-[5-[N-(5-chloro-3,4-dihydro-2-methyl-4-oxoquinazolin-6-yl)methylamino]-2- thenoyl]-L-glutamic acid (7), the first reported thiophene analogues of 5-chloro-5,8-dideazafolic acid, were synthesized and tested as inhibitors of tumor cell growth in culture. 4-Chloro-5-methylisatin (10) was converted stepwise to methyl 2-amino-5-methyl-6-chlorobenzoate (22) and 2-amino-5-chloro-3,4-dihydro-6-methyl-4-oxoquinazoline (19). Pivaloylation of the 2-amino group, followed by NBS bromination, condensation with di-tert-butyl N-(5-amino-2-thenoyl)-L-glutamate (28), and stepwise cleavage of the protecting groups with ammonia and TFA yielded 6. Treatment of 9 with acetic anhydride afforded 2,6-dimethyl-5-chlorobenz[1,3-d]oxazin-4-one (31), which on reaction with ammonia, NaOH was converted to 2,6-dimethyl-5-chloro-3,4-dihydroquinazolin-4-one (33). Bromination of 33, followed by condensation with 28 and ester cleavage with TFA, yielded 7. The IC50 of 6 and 7 against CCRF-CEM human leukemic lymphoblasts was 1.8±0.1 and 2.1±0.8 μM, respectively.